The Application dimension of the COVID-19 Molecular Diagnostics market is divided into three principal sub‑segments: Diagnostic Testing, Surveillance, and Research. Diagnostic Testing represents the bulk of revenue, as hospitals and clinics require rapid, high‑accuracy nucleic‑acid detection to confirm infection and guide patient management. This sub‑segment drives roughly 70 % of total market value because of its continuous demand across acute care, outpatient, and point‑of‑care settings. Surveillance encompasses population‑level screening programs, wastewater monitoring, and workplace testing initiatives that support public‑health authorities in tracking viral spread. Although episodic, these activities account for about 20 % of market size, reflecting sizable procurement cycles during outbreak peaks. Research covers academic and pharmaceutical investigations, including vaccine efficacy trials and therapeutic target validation, contributing the remaining 10 % of revenue. Collectively, these applications define the overall COVID-19 Molecular Diagnostics segmentation, with each sub‑segment’s share directly linked to its usage intensity, regulatory mandates, and funding allocations.